B7IG fusion protein
    10.
    发明授权
    B7IG fusion protein 失效
    B7Ig融合蛋白

    公开(公告)号:US5580756A

    公开(公告)日:1996-12-03

    申请号:US219518

    申请日:1994-03-29

    摘要: The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.

    摘要翻译: 本发明将B7抗原鉴定为与T细胞上的CD28受体反应的配体。 描述了B7抗原和CD28受体的片段和衍生物,包括与编码部分人免疫球蛋白Cγ1的氨基酸序列连接的与B7或CD28的细胞外结构域相对应的氨基酸序列的融合蛋白。 提供了使用B7抗原,其片段和衍生物以及CD28受体,其片段和衍生物以及与B7抗原和/或CD28受体反应的抗体和其它分子调节CD28阳性T细胞应答的方法,以及 由T细胞介导的免疫应答。 本发明还包括检测与介导细胞间粘附的细胞受体反应的配体的测定方法。